Neonc Technologies (NASDAQ:NTHI) Stock: Insider Amir Heshmatpour Acquires 40,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 40,000 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The shares were purchased at an average cost of $3.39 per share, with a total value of $135,600.00. Following the acquisition, the chief executive officer directly owned 3,253,000 shares of the company’s stock, valued at approximately $11,027,670. This trade represents a 1.24% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neonc Technologies Trading Up 16.8%

Shares of NASDAQ NTHI opened at $4.37 on Wednesday. Neonc Technologies Holdings, Inc. has a 52 week low of $2.50 and a 52 week high of $12.00. The business’s 50 day moving average price is $3.30 and its 200 day moving average price is $5.34.

Neonc Technologies (NASDAQ:NTHI) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Hedge Funds Weigh In On Neonc Technologies

Large investors have recently made changes to their positions in the company. Bank of America Corp DE purchased a new stake in Neonc Technologies during the second quarter worth $1,017,000. BlackRock Inc. acquired a new stake in Neonc Technologies during the second quarter valued at $815,000. Westmount Partners LLC grew its position in Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after buying an additional 153,858 shares during the period. Finally, Global Retirement Partners LLC purchased a new position in Neonc Technologies in the second quarter valued at $126,000.

Analyst Ratings Changes

Several brokerages recently issued reports on NTHI. Roth Capital started coverage on shares of Neonc Technologies in a report on Thursday, September 24th. They set a “buy” rating for the company. Wall Street Zen raised Neonc Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. BTIG Research reiterated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, September 8th. Finally, Zacks Research raised Neonc Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, November 5th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Neonc Technologies

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.